PrECOG, LLC, today announced the publication of final results from the pivotal phase 3 PATINA study in the New England ...

Adding Ibrance to maintenance therapy extends progression-free survival by 15.2 months in HR-positive, HER2-positive ...

HER2-positive breast cancer is driven by HER2 protein overexpression, historically linked to poor outcomes but now improved by targeted therapies. Treatment varies by stage, involving surgery, ...

The Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance and Faslodex.

Experts discuss the current status of neoadjuvant ADC therapies, eligibility criteria, and future treatment pathways for high-risk patients.

Elissa Kalver was 34 when she found a lump in her breast. She had no family history of cancer and had just welcomed her first child. She assumed the lump was a cyst. But when she went to get it ...